transmembrane protein 256 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored TMEM256P2 profile across patient tissues and cancer cell-line models. TMEM256P2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TMEM256P2 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, TMEM256P2 RNA expression shows 9,583 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, HNSC, and PDAC as cancer lineages where TMEM256P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM256P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM256P2 survival associations across molecular data types. TMEM256P2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM256P2 RNA expression–survival associations across cancer types. High TMEM256P2 expression shows unfavorable associations in BRCA, OV, ESCA, LGG and SKCM, but favorable associations in LUSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify BRCA as the clearest survival context for TMEM256P2 RNA expression.
This table summarizes TMEM256P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM256P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM256P2 shows higher tumor expression in HNSC and LUAD. The HNSC box plot shows higher TMEM256P2 RNA expression in tumor versus normal tissue (log2 FC = +0.094, t-test p = .021).
This table shows molecular features associated with TMEM256P2 in patient tissues and cancer cell lines. In patient samples, TMEM256P2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
